Related Experiment Videos
Hair to document exposure to glibenclamide
Marion Villain1, Christine Tournoud, Françoise Flesch
1ChemTox, 3 rue Gruninger, 67400 Illkirch, France.
Summary
This study introduces a new hair testing method for glibenclamide, an antidiabetic drug, to detect its use in incapacitating victims. Glibenclamide was detected in hair samples, indicating repetitive exposure, which is crucial for forensic investigations.
Area of Science:
- Forensic Toxicology
- Analytical Chemistry
- Pharmacology
Background:
- Glibenclamide, an antidiabetic medication, is not typically associated with drug-facilitated crimes.
- Victim incapacitation for criminal purposes often involves sedative or intoxicating substances.
- There is a need for reliable methods to detect drugs like glibenclamide in forensic contexts.
Purpose of the Study:
- To develop and validate an original method for glibenclamide detection in hair samples.
- To assess the utility of hair testing for glibenclamide in forensic casework.
- To correlate hair glibenclamide concentrations with drug administration.
Main Methods:
- A liquid/liquid extraction method was employed for glibenclamide isolation from hair.
- High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was used for sensitive detection.
- Hair samples were analyzed using specific mass transitions (m/z 493.9 to 168.9 and 493.9 to 368.8).
Main Results:
- The developed method demonstrated linearity from 5 to 1000 pg/mg with a limit of quantification at 5 pg/mg.
- Glibenclamide was detected in positive hair samples (23 pg/mg and 31 pg/mg in consecutive segments), suggesting repetitive exposure.
- Hair concentrations correlated with single and daily dose administrations, with 5 pg/mg after a single 5mg dose and 650 pg/mg after a 20mg/day dose.
Conclusions:
- The developed hair testing method is suitable for forensic analysis of glibenclamide.
- Positive glibenclamide findings in hair can indicate repetitive drug administration, relevant in cases of victim incapacitation.
- Hair analysis provides valuable insights into drug exposure history in forensic investigations.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...